Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2019 May 9;21:116. doi: 10.1186/s13075-019-1898-7

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author(s). 2019

Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.

PMC Copyright notice

Fig. 4 — a–e IHC staining for CD31 on ST of patients with naïve or MTX-IR PsA and Ab^neg RA patients. Example photos of CD31 (DAB) staining of ST biopsies from patients with naïve (a) or MTX-IR (b) PsA and with naïve (c) or MTX-IR (d) Ab^neg RA (magnification × 20 and magnification × 40 in the corresponding inset). Thin black arrows indicate CD31⁺ vessels (brown) in the corresponding inset. e Synovial CD31⁺ vessel count in PsA and Ab^neg RA patients divided by treatment regimen; *p = 0.01, naïve vs MTX-IR PsA patients; *p < 0.001, naïve vs MTX-IR Ab^neg RA patients. IHC immunohistochemistry, PsA psoriatic arthritis, RA rheumatoid arthritis, Ab autoantibody, MTX-IR methotrexate inadequately responder, CD cluster designation